Droxidopa (Standard)

Droxidopa (Standard) is the analytical standard of Droxidopa. This product is intended for research and analytical applications. Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) [1][2][3][4].

Product Specifications

CAS Number

[23651-95-8]

Product Name Alternative

L-DOPS (Standard) ; DOPS (Standard) ; SM5688 (Standard)

UNSPSC

12352005

Target

Adrenergic Receptor; Reference Standards

Type

Reference Standards

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/droxidopa-standard.html

Smiles

OC1=C(O)C=CC([C@@H](O)[C@@H](C(O)=O)N)=C1

Molecular Formula

C9H11NO5

Molecular Weight

213.19

References & Citations

[1]Horacio Kaufmann, et al. Droxidopa for neurogenic orthostatic hypotension. Neurology, 2014; 83 (4) .|[2]Dela Peña I, et al. Droxidopa alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats. Eur J Pharmacol. 2021 Feb 5;892:173826.|[3]Cao LF, et al. Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease. Neural Plast. 2016;2016:6383240. |[4]Kaufmann H. L-dihydroxyphenylserine (Droxidopa) : a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res. 2008 Mar;18 Suppl 1:19-24.